Antibody Ingredients TRIZ Cases

Segmenting 4-1BB agonists from ADCC antibodies enhances immune responses while minimizing autoimmune side effects.

Antibodies bind the MFAP4 integrin motif to block receptor interaction, preventing neointima formation and restenosis after percutaneous coronary intervention.

A monoclonal antibody targeting CD66c on myeloid-derived suppressor cells eliminates immunosuppressive activity via antibody-dependent cellular cytotoxicity.

Ianalumab targets BAFF-R to deplete B cells, reducing corticosteroid requirements and moderate flares while maintaining disease control.

Adsorbing specific antibodies onto PPSU nanoparticles prevents anaphylaxis by blocking allergen-induced mast cell activation.

Targeted anti-CXCR5 antibodies modulate B cell activity without broad immunosuppression, addressing incomplete symptom control in current lupus therapies.

Anti-FOLR1 antibodies target N-glycosylated epitopes to resolve low specificity in diagnostic assays and eliminate complex sample pre-treatment steps.

Linkers reconnect cleaved interchain disulfide bonds after attaching cytotoxic agents, preserving antibody stability and binding affinity.

Engineered anti-ROR1 antibodies internalize into target cells, resolving low specificity and efficacy in antibody-drug conjugates.

MOR202 targets CD38+ plasma cells to reduce autoantibody titers while sparing low-expression immune cells.

Merges Treg depletion with LTBR agonism to overcome limited therapeutic duration in cancer treatment.

A humanized PD-1 antibody blocks the PD-1/PD-L1 interaction to enhance T cell activation.

Bispecific antibodies bind extracellular domains of PD-1 and LAG3, blocking inhibitory signaling to restore T-cell activation against tumors.

Antibodies bind specific conformational epitopes to stabilize the Notch 3 receptor in an autoinhibited state, blocking ligand-dependent signal transduction.

Engineered 1F11 antibody reverses immunosuppression and boosts INFγ production while maintaining species selectivity across tumor cell lines.

Combining anti-GITR agonist antibodies with anti-PD-1 agents activates NK cells and CD8+ T cells to drive tumor regression.

Anti-CD30 antibody-drug conjugates target CD30-expressing lymphomas to induce tumor regression in patients.

Anti-MASP-1 antibodies target unique MASP-1 epitopes to block complement activation, resolving specificity issues between MASP-1 and MASP-3.

A trivalent bispecific antibody recruits cytotoxic T cells to cancer cells via simultaneous binding to CD3 and claudin antigens.

Conjugating PSMA antibodies to toxins through non-natural amino acid linkers targets extracellular epitopes, improving imaging and therapeutic efficacy.

Cleavable linkers mask CD3 binding domains to prevent peripheral toxicity, enabling selective T cell engagement only within the tumor microenvironment.

Affinity-matured antibodies targeting Globo H, SSEA-3, and SSEA-4 address glioblastoma resistance by blocking tumor activities and enabling sensitive detection.

Anti-CD6 monoclonal antibodies bind CD6 domain 1 to block T cell activation, lowering IL-6 and CRP concentrations during extracorporeal procedures.

MSR1 inhibitors deactivate macrophages to treat autoimmune neuropathies by blocking specific biological molecules that cause ongoing nerve damage.

An anti-human GPVI antibody targets platelet activation to prevent thrombosis in acute ischemic stroke patients.

Modified hinge regions prevent receptor dimerization, eliminating agonistic effects while maintaining therapeutic efficacy.

Engineered anti-CD19 antibodies overcome CD20 resistance by optimizing glycosylation to boost ADCC and CDC efficacy.

Modifying the Fc region of an anti-C5 antibody reduces immunogenicity and ADCC/CDC function, extending half-life for safer subcutaneous administration.

Anti-Siglec-9 antibodies bind sialic acid receptors to increase natural killer cell activity, countering cancer-induced immune suppression.

Antibody-cytotoxic conjugates target GPC3-positive cancer cells, reducing normal tissue damage while maintaining therapeutic effectiveness.

Zinc mimicry compounds stimulate antibody production against anthrax lethal factor and MMP-7, bypassing delayed antibiotic efficacy.

A CD9-specific human antibody binds the CD9 extracellular loop 2 domain to neutralize antigen activity.

Merges broad immune modulation with targeted allergen tolerance to suppress IgE and IL-4, reducing injection frequency.

Proteolytic cleavage unmasks CD47 binding on a bispecific protein, reducing toxicities from healthy cell exposure.

A MASP-2 inhibitory agent selectively blocks the lectin complement pathway to treat renal fibrosis.

Administering sacituzumab govitecan alongside anti-PD-1 antibodies achieves 44-75% objective response rates in metastatic non-small cell lung cancer patients.

Humanized antibody hD11-5 targets HLA-A2/TyrD369-377 complexes, resolving low intrinsic affinity limits in TCR-like designs.

An antibody binds specifically to the partial CAPRIN-1 polypeptide on cancer cell surfaces.

Antibodies targeting HER-3 reduce tumor growth and metastasis by blocking signaling, overcoming limited efficacy of single-target therapies.

Monoclonal antibodies bind the extracellular domain of HER3 to block receptor dimerization.

Immobilizing antibodies on solid supports enables selective disulfide reduction and uniform drug loading for antibody screening.

IL-31RA antagonists inhibit the IL-31 pathway, resolving inflammation and pruritus in dermatological disorders.

Anti-CD46 antibodies bind tumor-initiating cells to reduce recurrence and metastasis.

Segmenting immune responses into measurable T-cell and dendritic cell ratios identifies effective patient groups, avoiding ineffective treatments.

Periodic Campath-1H cycles minimize autoimmune adverse events while maintaining therapeutic efficacy.

Targeting human tryptophanyl-tRNA synthetase with blocking agents prevents EV-A71 infection while avoiding the specificity limits of direct viral targeting.

Merging chiauranib with PD-1 inhibitors establishes fixed-ratio dosing to resolve efficacy prediction complexity while reducing toxicity.

Anti-BMPR1B antibodies bind BMPR1B determinants on cancer stem cells, eliminating tumorigenic populations that resist standard therapies.

Anti-glycPD-L1 antibodies target glycosylated PD-L1 to block immunosuppression and enhance T-cell activity while avoiding autoimmune responses.

A MASP-2 inhibitory antibody targets the lectin pathway to block complement activation and prevent microvascular endothelial cell injury.